Why Is HeartBeam ($BEAT) Stock Up +67.56% Today? (Find out why any stock moved today on Tickeron.) BEAT shares surged roughly 67.6% Monday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its at-home heart attack assessment technology. The designation covers the company's 3D ECG platform as a tool to help physicians assess a possible heart attack when symptoms begin, wherever the patient is. Breakthrough status provides prioritized FDA review and is a prerequisite for certain expedited Medicare coverage pathways. The stock ran as high as roughly 90% intraday before pulling back, reflecting heavy speculative volume in a low-priced, high-volatility name. Broader markets were mildly higher, but the move was overwhelmingly company-specific rather than sector-driven. $SNOW $APPN $NNDY $ZS